CD4 and inflammatory bowel disease: (96) found that a novel dual TORC1/2 inhibitor, AZD8055, promotes Treg cell differentiation in the colon of DSS-induced IBD mice, increases the percentage of Treg cells, and reduces the number of colonic CD4+ T cells, Th1 and Th17 cell activation, and cytokine production.